China Resources Pharmaceutical Group (HKSE:03320) Long-Term Capital Lease Obligation : HK$924 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group Long-Term Capital Lease Obligation?

China Resources Pharmaceutical Group's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$924 Mil.

China Resources Pharmaceutical Group's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (HK$860 Mil) to Jun. 2023 (HK$969 Mil) but then declined from Jun. 2023 (HK$969 Mil) to Dec. 2023 (HK$924 Mil).

China Resources Pharmaceutical Group's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (HK$933 Mil) to Dec. 2022 (HK$860 Mil) but then increased from Dec. 2022 (HK$860 Mil) to Dec. 2023 (HK$924 Mil).

China Resources Pharmaceutical Group Long-Term Capital Lease Obligation Historical Data

The historical data trend for China Resources Pharmaceutical Group's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group Long-Term Capital Lease Obligation Chart

China Resources Pharmaceutical Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1,632.36

1,154.58

932.91

860.17

924.13

China Resources Pharmaceutical Group Semi-Annual Data
	Dec13	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															932.91	945.00	860.17	969.18	924.13

China Resources Pharmaceutical Group (HKSE:03320) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

China Resources Pharmaceutical Group Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

China Resources Pharmaceutical Group (HKSE:03320) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

640:Germany

Address

26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG

Website

https://www.crpharm.com

CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.

Executives

Bei Jing Guo You Zi Ben Yun Ying Guan Li You Xian Gong Si

2201 Interest of corporation controlled by you

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines